Publications

Reply to N. Fazio

O'Reilly EM, Park W, Kelsen DP

Reply to Nutritional support in pancreatic cancer

Moffat GT, Epstein AS, O'Reilly EM

Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study

Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, et al.

Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively.

M Malla, LJ Huebner, S Piawah, HJ Lenz, CD Blanke, JA Meyerhardt, ...

Signet ring cell carcinoma of the Ampulla of Vater: outcomes of patients in the United States

Kinslow CJ, May MS, Kozak M, Pollom EL, Chang DT

SO-3 Maintenance olaparib in patients aged≥ 65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

H Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, M Hall, J Park, ...

Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: MyCare-009-05.

GT Moffat, D Watson, S Kapoor, KG Ghosh Roy, R Parashar, A Alam, ...

The evolutionary origins of recurrent pancreatic cancer

H Sakamoto, MA Attiyeh, JM Gerold, AP Makohon-Moore, A Hayashi, ...

The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma

GT Moffat, EM O’Reilly

Time to Reconsider Staging Laparoscopy in Pancreatic Cancer? Reply

EM O'Reilly, C Ferrone

Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.

AM Varghese, I Singh, RR Singh, M Capanu, JF Chou, W Wong, ...

A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic …

J Bendell, D Rasco, W Park, L Zhou, A Galkin, D Slee, L Carter, D Nickle, ...

A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic …

MH O’Hara, EM O'Reilly, M Rosemarie, G Varadhachary, ZA Wainberg, ...

A phase II study of ADI-PEG 20 and FOLFOX6 in patients (pts) with advanced hepatocellular carcinoma (HCC).

JJ Harding, S Qin, TS Yang, CJ Yen, Y Chao, TE Wang, RKG Do, ...

A randomized phase II study of cabiralizumab (cabira)+ nivolumab (nivo)±chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).

A Wang-Gillam, EM O'Reilly, JC Bendell, ZA Wainberg, EH Borazanci, ...

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, et al.

A synonymous germline variant PALB2 c. 18G> T (p. Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers

C Yang, O Ceyhan-Birsoy, D Mandelker, S Jairam, A Catchings, ...

Ablative RT results in excellent local control and survival in localized pancreatic cancer

M Reyngold, E O'Reilly, M Zinovoy, PB Romesser, AJ Wu, C Hajj, ...

Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in …

MH O'Hara, EM O'Reilly, M Rosemarie, G Varadhachary, ZA Wainberg, ...

Abstract I14: Polymerase theta synthetic lethal interaction in homologous recombination-deficient pancreatic ductal adenocarcinoma

A Wang, A Zamperone, M Sohail, L Wang, F Balogun, J Li, E Zhao, ...

Abstract No. 617 Nonthermal ablation of pancreatic cancer in a pig model, using vascular-targeted photodynamic therapy (VTP)

H Yarmohammadi, F Nurili, M Fujimori, S Monette, D Kelsen, J Coleman, ...

Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

AM Schram, EM O’Reilly, R Somwar, R Benayed, S Shameem, ...

Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes

Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, et al.

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma …

M Reni, H Riess, E O’Reilly, A Santoro, J Park, T Bekaii-Saab, M Tempero, ...

Analysis of patient screening in the phase III, international, randomized, open-label APACT trial

M Reni, J Winter, G Tortora, U Pelzer, H Riess, H Chang, E O’Reilly, D Oh, ...

APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant</i> nab<//i>-Paclitaxel Plus Gemcitabine (</i> nab<//i>-P/G) Versus Gemcitabine (G) for …

A Ko, M Reni, H Riess, U Pelzer, EM O'Reilly, J Winter, DY Oh, CP Li, ...

Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial

GK Abou-Alfa, Q Shi, JJ Knox, A Kaubisch, D Niedzwiecki, J Posey, ...

Association of pancreatic cancer stem cells with tumor stroma type.

IH Sahin, G Askan, JF Chou, M Capanu, KH Yu, O Basturk, ...

Associations of physical activity with survival and progression in metastatic colorectal cancer: results from cancer and leukemia group B (Alliance)/SWOG 80405

BJ Guercio, S Zhang, FS Ou, AP Venook, D Niedzwiecki, HJ Lenz, ...

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, …

Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers

MA Lowery, M Bradley, JF Chou, M Capanu, S Gerst, JJ Harding, IE Dika, ...

BRCA-mediated tumorigenesis is origin and cell-type dependent

P Jonsson, ML Cheng, C Bandlamudi, P Srinivasan, SS Chavan, ...

Cardiac biomarkers and risk of atrial fibrillation in chronic kidney disease: the CRIC study

JA Lamprea‐Montealegre, LR Zelnick, MG Shlipak, JS Floyd, ...

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, et al.

Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, … Park W, …

Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes

M Salem, K Kadakia, S Trufan, J Hwang, R Nazemzadeh, M Jagosky, ...

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, et al.

Dhani N Renouf DJ Lee MA Sun W et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial

EM O’reilly, DY Oh

Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial

EM O’Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, G Fisher, ...

Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.

NP Raj, Y Zheng, V Kelly, S Katz, JF Chou, RKG Do, M Capanu, ...

EP1. 01-61 iSEND Model as a Predictor of Efficacy in Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer: Fukushima Cohort

N Okabe, H Mine, H Takagi, M Watanabe, S Muto, T Hasegawa, Y Shio, ...

Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution

JM Creasy, DA Goldman, M Gonen, V Dudeja, EM O'Reilly, GK Abou-Alfa, ...

Extended mutational profiling by MSK-IMPACTTM identifies mutations predicting thromboembolic risk in patients with solid tumor malignancy

A Dunbar, K Bolton, SM Devlin, F Sanchez-Vega, J Gao, JV Mones, ...

Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.

V Florou, W Park, PJ Hosein, BA Wilky, JC Trent, G Lopes

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine

S Mondaca, P Razavi, C Xu, M Offin, M Myers, M Scaltriti, JF Hechtman, ...

Genomic landscape of pancreatic adenocarcinoma in younger versus older patients: does age matter?

I Ben-Aharon, M Elkabets, R Pelossof, KH Yu, CA Iacubuzio-Donahue, ...

Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review

Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

P Hammel, HL Kindler, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ...

Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).

W Park, W Wong, KH Yu, AM Varghese, N Riaz, VP Balachandran, ...

How I Treat Metastatic Pancreatic Cancer With Chemotherapy

BA Krantz, EM O’Reilly